Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
to evaluate the safety and efficacy of the use of R-MPV followed by high-dose chemotherapy using thiotepa, cyclophosphamide and busulfan with stem cell rescue in patients with newly diagnosed PCSNL.
1-year event-free survival and acute treatment-related toxicity.
Yes
Antonio Omuro, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
04-129
NCT00596154
December 2004
December 2013
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Memorial Sloan-Kettering Cancer Center at Commack | Commack, New York 11725 |
Memorial Sloan-Kettering at Basking Ridge | Basking Ridge, New Jersey 07920 |